Iovance Biotherapeutics Inc (IOVA) Share Price

You can tell that the HF are on board with this increase relative to the way it trades. The technical levels were all respected on the 5 min chart. 1. Retracement to 1 day - 61.8 was almost to the exact penny at 8.90 (this is a typical buy point level for traders if it holds). It held and took off. 2. It basically rode the 9 EMA and would bounce off of 20 EMA (up until EOD profit taking). You only typically see this respect of technical levels when the big money is on board.

On a larger frame - We broke and held both 200 SMA and 50 SMA on daily .
Volume on bid was there all day with no overpowering volume on the ask.
IMO - we are in the midst of a shift with short covering and accumulation. Technical traders set alerts when 200 SMA are remounted and held. So I would think that more buying interest will show up.

Badger, fantastic find & very intriguing read!
Iovance is on deck or in the hole, as Wayne n his team stay Patient as time alone will catapult Iovance’s Merck (most likely to me) buyout comes in 2025/2026
For $125-$165 in my opinion.

We need: Front Line w/Keytruda (Merck exclusivity runs out soon in 2028)

NSCLC-Accelerated Approval

Head/Neck/Throat or Cervical Accelerated Approval.

3-Approved indications along w approvals in EU, Canada, Australia & Japan all probable, takes us well into the triple digits, buyout wise.

Wayne in my opinion will NOT just settle on a lower buyout due to his failure to see the forest thru the tree$ in his Acerta deal.

He knows all too well how Pharmacylcics (spelling off) got to $325….

Our Maz Buyout under this laid out above is $245 with stock options n future royalties, in my opinion.

Time will tell n be PATIENT.

#CureCancer

OT, but to paint a picture of all the M&A activity this year:
*********************************************************************************
(This was pulled from Contract Pharma, https://www.contractpharma.com/ )

2024 Pharmaceutical Industry Mergers & Acquisitions Roundup
A quick reference of all the mergers and acquisitions that took place within the global pharmaceuticals market in 2024.

2024 Pharmaceutical Industry Mergers & Acquisitions Roundup
Charles Sternberg, Associate Editor 01.31.24
The global pharmaceutical industry witnesses an excess of merger and acquisition (M&A) activity every year—probably more than most other industries—both in the number of deals and the amount of money spent on M&A.

From big game-changing deals to smaller yet still significant transactions, M&A is an integral part of the operations of pharma companies, especially as the cost of drug development consistently increases year-after-year.

Below is a frequently updated list of all the transactions that have taken place within 2024. Return often to stay informed on the latest deals occurring within the industry and to get a brief recap of the most important details.

Thermo Fisher Scientific—Olink
Thermo Fisher Scientific Inc. completed its acquisition of Olink Holding AB, a provider of next-generation proteomics solutions.
Date of announcement: July 10, 2024
Value: $3.1 billion

Lilly—Morphic
Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Date of announcement: July 8, 2024
Value: undisclosed

Medpharm—Tergus Pharma
MedPharm, a global topical and transdermal CDMO and an Ampersand Capital Partners portfolio company, is merging with Tergus Pharma, a Great Point Partners portfolio company.
Date of announcement: July 8, 2024

Olon Group—GTP Bioways
Olon Group acquired GTP Bioways Group, a French company operating as Biotech CDMO and specializing in R&D services, process development and production of mAbs, enzymes, proteins, nanodrugs, ADCs and fill-finish.
Date of announcement: July 3, 2024
Value: undisclosed

Alcon—BELKIN
Alcon, a global leader in eye care, has acquired BELKIN Vision, including BELKIN Vision’s Direct Selective Laser Trabeculoplasty (DSLT) technology, expanding Alcon’s glaucoma portfolio with a first-line therapy.
Date of announcement: July 1, 2024
Value: $81 million

Rhenopharma—Konapharma
Rhenopharma Group has acquired Konapharma AG, a Swiss contract manufacturer for the pharmaceutical industry. Within the new group of companies, Konapharma now complements the services of packaging company Allpack and Rhenochem.
Date of announcement: June 27, 2024
Value: undisclosed

CatSci—Reach Separations
CatSci Ltd, an innovation partner for medicines development, has acquired Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics.
Date of announcement: June 26, 2024
Value: undisclosed

ANI Pharmaceuticals—Alimera Sciences
ANI Pharmaceuticals Inc. agreed to acquire Alimera Sciences Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with maintaining better vision longer.
Date of announcement: June 24, 2024
Value: $381 million

Great Point Partners—Lyocontract GmbH
Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, acquired Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization (CDMO) based in Ilsenburg, Germany.
Date of announcement: June 13, 2024
Value: undisclosed

Ono—Deciphera Pharmaceuticals
Ono Pharmaceutical Co. Ltd. completed its previously announced tender offer to acquire all outstanding shares of common stock of U.S. biopharmaceutical company Deciphera Pharmaceuticals Inc. through its wholly-owned subsidiary, Topaz Merger Sub Inc.
Date of announcement: June 12, 2024
Value: $2.4 billion

EQT—CluePoints
The EQT Healthcare Growth Strategy and the EQT Growth Fund agreed to acquire a majority stake in CluePoints, with meaningful reinvestment from the management team and existing shareholders Summit Partners and Clinimetrics SA.
Date of announcement: June 12, 2024
Value: undisclosed

Aterian Investment Partners—CPL
One of Aterian Investment Partners’ affiliates closed its acquisition of Contract Pharmaceuticals Ltd. Canada, a North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
Date of announcement: June 6, 2024
Value: Undisclosed

Formosa Labs—Synchem
Formosa Laboratories, Inc., an API supplier and CDMO headquartered in Taiwan, completed its acquisition of SynChem, Inc., a contract research laboratory located in suburban Chicago. SynChem will now operate under the new name SynChem-Formosa.
Date of announcement: June 4, 2024
Value: Undisclosed

Merck—EyeBio
Merck, known as MSD outside of the United States and Canada, entered into a definitive agreement under which it will acquire Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company.
Date of announcement: May 29, 2024
Value: $3 billion

Asahi Kasei—Calliditas
Asahi Kasei Corp. offered to acquire the shares of the pharmaceutical company Calliditas Therapeutics AB to make Calliditas a wholly-owned subsidiary of Asahi Kasei.
Date of announcement: May 28, 2024
Value: $1.1 billion

Orna Therapeutics—ReNAgade
Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA), has acquired ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics.
Date of announcement: May 23, 2024
Value: Undisclosed

MilliporeSigma—Mirus Bio
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, signed a definitive agreement to acquire Mirus Bio.
Date of announcement: May 23, 2024
Value: $600 million

Biogen—HI-Bio
Biogen Inc. and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), entered into a definitive agreement under which Biogen will acquire HI-Bio.
Date of announcement: May 22, 2024
Value: $1.15 billion upfront and up to $650 million in potential milestone payments

Johnson & Johnson—Proteologix
Johnson & Johnson entered a definitive agreement to acquire Proteologix Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases.
Date of announcement: May 16, 2024
Value: $850 million in cash, with potential for an additional milestone payment

Selvita—PozLab
Selvita S.A. completed its strategic acquisition of PozLab, a CDMO offering drug product development services and small pilot plant capabilities, including analytical, formulation, and process development competencies, followed by microbiological testing.
Date of announcement: May 7, 2024
Value: Undisclosed

LSL Pharma—Target Co.
LSL Pharma Group Inc., a Canadian integrated pharmaceutical company, entered into a binding Letter of Intent to acquire Target Co., a privately held, Quebec-based competing contract drug manufacturer (CDMO) specialized in the formulation, production, and marketing of natural products.
Date of announcement: May 6, 2024
Value: $2.5 million

Novartis—Mariana Oncology
Novartis agreed to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, MA focused on developing radioligand therapies (RLTs) to treat cancers.
Date of announcement: May 3, 2024
Value: $1 billion upfront + $750 million in payments upon completion of pre-specified milestones

Myonex—Creapharm
Myonex completed the acquisition of Creapharm's pharmaceutical services business.
Date of announcement: May 2, 2024
Value: Undisclosed

Ono Pharmaceuticals—Deciphera
Deciphera Pharmaceuticals LLC., a biopharmaceutical company, entered into a definitive merger agreement with Ono Pharmaceutical Company, Ltd. (ONO) under which ONO will acquire all outstanding shares of Deciphera common stock in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO.
Date of announcement: April 29, 2024
Value: $2.4 billion

Eli Lilly and Company—Nexus Pharmaceuticals
Eli Lilly and Company agreed to acquire a manufacturing facility from Nexus Pharmaceuticals, a leading sterile manufacturer in the pharmaceutical industry.
Date of announcement: April 24, 2024
Value: Undisclosed

Ku¨hne Holding AG—Aenova Group
Ku¨hne Holding AG agreed to acquire pharma contract development and manufacturing organization Aenova Group from international investment firm BC Partners.
Date of announcement: April 24, 2024
Value: Undisclosed

Incyte Corp.—Escient Pharmaceuticals
Incyte Corp. entered into a definitive agreement to acquire Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing small molecules for systemic immune and neuro-immune disorders.
Date of announcement: April 23, 2024
Value: $750 million plus Escient’s net cash remaining at the close of the transaction

Qinesca Solutions—Insife ApS
Qinecsa Solutions, a provider of technology pharmacovigilance solutions, acquired Insife ApS (Insife), a Danish-based software, technology, and consultancy firm specializing in developing pharmacovigilance platforms.
Date of announcement: April 11, 2024
Value: Undisclosed

Eliem Therapeutics—Tenet Medicines
Eliem Therapeutics Inc. and Tenet Medicines Inc., a development-stage private biotechnology company, have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.
Date of announcement: April 11, 2024
Value: $210 million

Vertex Pharmaceuticals Inc.—Alpine Immune Sciences Inc.
Vertex Pharmaceuticals Inc. and Alpine Immune Sciences Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share.
Date of announcement: April 11, 2024
Value: $4.9 billion

Essential Pharma—Renaissance Pharma
Essential Pharma, an international specialty pharma group, completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd., a clinical stage pharmaceutical company focused on the development of life-changing therapies in pediatric rare disease.
Date of announcement: April 9, 2024
Value: Undisclosed

CoreRx Inc.—Societal CDMO Inc.
CoreRx Inc. completed its previously announced acquisition of Societal CDMO Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics.
Date of announcement: April 9, 2024
Value: $130 million

Johnson & Johnson—Shockwave Medical
Johnson & Johnson entered into a definitive agreement to acquire all outstanding shares of Shockwave Medical, Inc.
Date of announcement: April 5, 2024
Value: $13.1 billion

Kintara Therapeutics—TuHURA Biosciences
Kintara Therapeutics Inc., a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc., a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline.
Date of announcement: April 3, 2024
Value: Undisclosed

Genmab—ProfoundBio
Genmab entered into a definitive agreement to acquire ProfoundBio Inc., a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRa-expressing solid tumors.
Date of announcement: April 3, 2024
Value: $1.8 billion

Bora Pharmaceuticals—Upsher-Smith Laboratories
Bora Pharmaceuticals Co., Ltd. completed the acquisition of Upsher-Smith Laboratories, LLC., a generics manufacturer and marketer based in Minnesota, from its sellers, Sawai Group Holdings and Sumitomo Corp. of Americas.
Date of announcement: April 2, 2024
Value: $210 million

Veeda Clinical Research—Heads
Veeda Clinical Research Ltd., a full-service contract research organization (CRO), acquired Heads, a privately held European CRO specializing in conducting clinical trials in oncology.
Date of announcement: March 26, 2024
Value: Undisclosed

Novo Nordisk—Cardior Pharmaceuticals
Novo Nordisk agreed to acquire Cardior Pharmaceuticals, an expert in the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart.
Date of announcement: March 25, 2024
Value: $1.12 billion

AbbVie—Landos Biopharma
AbbVie Inc. agreed to acquire Landos Biopharma Inc., a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
Date of announcement: March 25, 2024
Value: $137.5 million

Ampersand Capital Partners—Biologos LLC
Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, acquired Biologos LLC, a full-service manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera.
Date of announcement: March 20, 2024
Value: Undisclosed

AstraZeneca—Fusion Pharmaceuticals
AstraZeneca entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
Date of announcement: March 19, 2024
Value: $2.4 billion

Bristol Myers Squibb—Karuna Therapeutics
Bristol Myers Squibb completed its acquisition of Karuna Therapeutics, Inc. Karuna is now a wholly owned subsidiary of BMS.
Date of announcement: March 18, 2024
Value: $14 billion

AstraZeneca—Amolyt Pharma
AstraZeneca entered a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing treatments for rare endocrine diseases.
Date of announcement: March 14, 2024
Value: $1.05 billion

Novartis—IFM Due
Novartis exercised its option to acquire all outstanding capital stock of IFM Due, a subsidiary company of IFM developing small molecules that inhibit the cGAS-STING pathway.
Date of announcement: March 13, 2024
Value: $90 million upfront plus up to $745 million in milestones

Johnson & Johnson—Ambrx
Johnson & Johnson acquired Ambrx Biopharma Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs).
Date of announcement: March 7, 2024
Value: $2 billion

Eilean Therapeutics—Ness Therapeutics
Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies, acquired Ness Therapeutics Inc in an all-equity transaction.
Date of announcement: March 4, 2024
Value: Undisclosed

CoreRx—Societal CDMO
CoreRx Inc. agreed to acquire Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.
Date of announcement: February 29, 2024
Value: $130M

Ginkgo Bioworks—Patch Biosciences
Ginkgo Bioworks acquired Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32.
Date of announcement: February 28, 2024
Value: Undisclosed

Ginkgo Bioworks—Proof Diagnostics
Ginkgo Bioworks acquired Proof Diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases.
Date of announcement: February 28, 2024
Value: Undisclosed

Telix Pharmaceuticals—IsoTherapeutics Group
Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC, a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas.
Date of announcement: February 27, 2024
Value: $8M upfront + milestone payments

AstraZeneca—Gracell Biotechnologies
AstraZeneca successfully completed its acquisition of Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition.
Date of announcement: February 23, 2024
Value: Undisclosed

Telix—QSAM
Telix agreed to acquire QSAM Biosciences Inc.—a U.S.-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer—and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
Date of announcement: February 13, 2024
Value: Undisclosed

Exponent—Chanelle Pharma
Chanelle Pharma, Ireland’s largest indigenous manufacturer of generic pharmaceuticals for animal and human health, was sold by its founder Michael H Burke to Exponent, a private equity firm.
Date of announcement: February 13, 2024
Value: Undisclosed

BioVaxys—IMV Inc.
BioVaxys Technology Corp. acquired the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX immune educating platform technology, developed by IMV Inc., Immunovaccine Technologies Inc., and IMV USA (IMV).
Date of announcement: February 12, 2024
Value: $750,000 upfront cash payment

AbbVie—Immunogen
AbbVie completed its acquisition of ImmunoGen Inc., which is now part of AbbVie, gaining its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
Date of announcement: February 12, 2024
Value: Not disclosed

Gilead Sciences—CymaBay Therapeutics
Gilead Sciences Inc. entered a definitive agreement under which it will acquire CymaBay Therapeutics Inc.
Date of announcement: February 12, 2024
Value: $4.3 billion

Jazz Pharmaceuticals—Redx Pharma
Jazz Pharmaceuticals plc and Redx Pharma plc signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program.
Date of announcement: February 8, 2024
Value: $10 million upfront

Novartis—MorphoSys AG
Novartis entered an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing oncology medicines.
Date of announcement: February 6, 2024
Value: €2.7 billion ($2.9 billion)

Novo Holdings—Catalent
Catalent Inc., a global CDMO headquartered in New Jersey, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction.
Date of Announcement: February 5, 2024
Value: $16.5 billion

Biovian—3P
Biologics CDMOs Biovian and 3P Biopharmaceuticals combined with the aim of establishing a new pan-European leader in their field.
Date of Announcement: February 2, 2024
Value: Gross sales exceed $81 million

Regeneron—2seventy Bio
Regeneron Pharmaceuticals Inc. formed Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc., under which it acquired full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities.
Date of Announcement: January 30, 2024
Value: $5 million and a single milestone payment

Avrobio—Tectonic Therapeutic
Avrobio Inc., a clinical stage gene therapy company, and Tectonic Therapeutic Inc., a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, entered into a definitive merger agreementto combine in an all-stock transaction.
Date of Announcement: January 30, 2024
Value: Not disclosed

Oxford Biomedica—ABL Europe
Oxford Biomedica plc, a quality and innovation-led cell and gene therapy CDMO, completed its previously announced acquisition of ABL Europe SAS from Institut Mérieux SA.
Date of Announcement: January 29, 2024
Value: $16.3 million

Bruker—Chemspeed Technologies
Bruker Corp. entered a definitive agreement to acquire Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions.
Date of Announcement: January 25, 2024
Value: Not disclosed

Sandoz—CIMERLI
Sandoz, a generic and biosimilar medicines company, signed an agreement to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc.
Date of Announcement: January 24, 2024
Value: $170 million upfront

Sanofi—Inhibrx
Sanofi entered into a definitive agreement under which its subsidiary Aventis Inc. will acquire all assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently in a registrational trial for the treatment of alpha-1 antitrypsin deficiency (AATD).
Date of Announcement: January 24, 2024
Value: $2.2 billion

Bora Pharmaceuticals—Upsher-Smith
Bora Pharmaceuticals acquired Upsher-Smith Laboratories, a generics manufacturer based in Minnesota.
Date of Announcement: January 23, 2024
Value: $210 million

Alcami—Pacific Pharmaceutical Services
Alcami Corporation, a contract development and manufacturing organization (CDMO), completed the acquisition of Pacific Pharmaceutical Services (PPS), a preferred provider of cGMP pharma storage and services.
Date of Announcement: January 19, 2024
Value: Not disclosed

Iuvo BioScience—Promedica International
iuvo BioScience, a specialty PRO (Partner Research Organization) providing preclinical and clinical development services, lab services, and scientific consulting, acquired Promedica International, a California Corp. (PMI), a specialty ophthalmology-focused clinical CRO.
Date of Announcement: January 18, 2024
Value: Not disclosed

Kindeva Drug Delivery—Summit Biosciences
Kindeva Drug Delivery acquired Summit Biosciences Inc., an intranasal drug-delivery CDMO, adding a new drug-delivery platform and further expanding Kindeva’s capabilities across a wider range of complex drug-device combination products (pulmonary, injectable, transdermal, and nasal).
Date of Announcement: January 18, 2024
Value: Not disclosed

Merck—Harpoon Therapeutics
Merck entered into a definitive agreement to acquire Harpoon Therapeutics Inc., which has a portfolio of novel T-cell engagers that employ the company’s Tri-specific T cell Activating Construct (TriTAC) platform.
Date of Announcement: January 9, 2024
Value: $680 million

Johnson & Johnson—Ambrx Biopharma
Johnson & Johnson entered into a definitive agreement to acquire Ambrx Biopharma Inc., a clinical-stage biopharmaceutical company with a synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs).
Date of Announcement: January 9, 2024
Value: $2 billion

GSK—Aiolos Bio
GSK plc entered into an agreement to acquire Aiolos Bio, Inc., a clinical-stage biopharmaceutical company focused on treatments for certain respiratory and inflammatory conditions.
Date of Announcement: January 9, 2024
Value: $1 billion upfront and as much as $400 million in success-based regulatory milestones

Novartis—Calypso Biotech
Novartis AG entered an agreement to acquire Calypso Biotech BV, a developer of Interleukin15 (IL-15) targeted therapies.
Date of Announcement: January 8, 2024
Value: $250 million upfront upon closing and potential development milestones of up to $175 million

Novartis—SanReno Therapeutics
SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of therapies for kidney diseases, has been acquired by Novartis. SanReno will become an indirect, wholly owned subsidiary of Novartis.
Date of Announcement: January 5, 2024
Value: Not disclosed

It answered your prayer. Back to 9.27.

Technically - looking solid here. Break and hold the 9.27 region and we could have a real squeeze here.

Over the weekend, I was contemplating the cash runway and potential for a cash raise. So we know they have said "well into H2 2025" but that does include a "conservative estimate of revenue", but exactly what does that mean? We know that they have cash as of Q1 2024 of $356M and the quarterly spend is between $80M-$85M. Taking the midpoint, the cash on hand would last 4.3 quarters ($356M/$82.5M) so assuming well into means thru Q3 2025, the revenue would need to cover the remaining 1.7 quarters or $139M (1.7x$82.5M). That would imply revenue of $23M/qtr for the 6 quarters (assuming no ramp). We are almost certain to beat $23M in Q2 and should ramp from there so I would say that calculation is ultra-conservative. I do think that they will raise capital, probably after Q3 or Q4 results, just to have a cushion for new trials/expansion, etc. Anyway, just a curious exercise.

Summer is the off season wait for 2025 and yess it will come

Plus - European acceptance of BLA.
Plus - Australia and UK submission

We have now Q2 results + Q3 guidance (hopefully) in August, a probable rate cut in September, Q3 results + FY guidance in Oct, another rate cut in Dec followed by 24 results + guidance for 25 in Jan.

If all goes well, we should be back > 15 level by Jan.

Our faith in this company will sooner or later pay off.

Gentlemen and Ladies. Even though I don't drink, tonight would be a good one to sit down and have a nice 25 yo Macallan neat. 👍️😁. Broke and held SMA 50 on weekly which is huge. The big one now is 9.02 200 SMA on daily. Typically need 3 taps of that price to get higher likelihood of break. Bids were definitely loading at key levels - sometimes with very large volume. Next week looks much brighter than the previous 18 next weeks.

this can't go that high lol, the truth with bio's is cringeworthy. Not too optimistic on big gains but definitely from the lows we saw earlier this week

Great! Run this to $100 this Summer and I will give you 10% of my profits! What a swell guy you are!

Everton44, Your a Complete Moron GO Away!

I control the market

Well, it is cheaper in paying for Comedy Club tickets!

Surfkast, I don't know if there's an answer that will make sense. I noticed that he/she has posted on over 130 different boards over the past several years. Certainly raises more than a few questions. Have a great day.

Serious question. Are you bi-polar? Last week you posted the following and now you are buying?

everton44

Re: everton44 post# 1266

Friday, July 05, 2024 12:37:58 PM

Post#
1267
of 1312
SOLD SHORT 11,388 MADE. TYVM IOVA! NEXT....

added 3500 at $9.00!

going to be a millionaire now. go IOVA!!!!!!!!!!!

Hicham, to your point and fwiw, iShares Russell 2000 ETF as of Jun 28, 2024 added 622,279 shares of IOVA and now stands at 6,157,247 shares. More interesting is the new position of IOVA that was created by the iShares Russell 2000 Growth ETF which as of Jun 28, 2024 is at 2,234,456 shares after their initial purchase. As more reports come in over the next several weeks, I'll be curious to see if and where any changes to positions in IOVA occurred. As for me, I do expect higher highs in the IOVA share price yet this year.

Good luck to you.

The net short position against Russell 2000 futures increased by 9.5 percentage points to 16.8% over 5 weeks, the largest such move over since March 2020 which caused the drop in Iovance and others and now it is payback time as the trend reverses, at least I hope.

Apparently a short squeeze is taking place. Hedge funds strategies have been heavile centred in 2024 on going long large-cap tech stocks and betting against other areas of the market, including small- and midcap stocks.

With the inflation figures yesterday and as money started flowing from megacap to small to mid cap a shott squeeze was initiated and according to some analysts this can last for a while as long as the probability of a rate cut in Sep remains high. If this continues until 6th of August and iovance reports good Q2 results and Q3 guidance then we are back > 12 to 15 before year end IMHO...

LoL... I have been modeling out the potential of NSCLC and hitting the 10,000 capacity from early on, so, although a lot of hurdles yet to clear, that is my 5 year target (which is why going from $18 to $7 made no sense unless I am wrong in my thinking). Issue is that if we get to $100, that would be about a $28B market cap which is what Seagen was before their buyout. They got a 33% premium on the takeover. The bigger you get, the less upside BP is willing to pay so that is why I think they will go it alone and just add new indications over time.

GMH, I think we have similar thoughts on numbers and when/how they can or will be achieved. The $100/share aspirations statement is not just a throw away comment, but I also don't think that number is achievable until and unless there are 2 or more indications approved and being treated: melanoma, nsclc, and maybe one additional type of cancer.

Should the company get to the point that 8,000+ patients are being treated each year, $3 billion per year and growing in revenue, and treatment centers and manufacturing capabilities on multiple continents, $100/share will be in the rearview mirror. I see the vision of what can be, but time is still needed to develop this great potential. What we don't know is what WR and this group of investors imagine for their own futures. There's history on these individuals, but as we age, our goals and motivations change as well. Is this company and TIL therapy to be their legacy? Or is this yet again a build and sell opportunity for them.

There is some incredible advances taking place right before our eyes, improvements will be made, newer and better ways of using TIL will be developed, and likely many different applications will become more obvious. But time is needed to accomplish all of these goals. The science is solid but the commercial application is still unproven. The good news is that recent indications are Iovance is succeeding and growing. We'll get a glimpse behind the current with the Q2, but it's still going to take several Q's of earnings to demonstrate the speed with which this new therapy will be taken up by the medical community and the company's ability to manage the logistical demands of this individualized type of treatment.

If we're guilty of anything, it's we've been thinking too small on this one. If we're guilty of anything else, it's we expected IOVA to hit $50 or more too fast. I like what I see, I'm in for the long haul at this point, and all indications are we're on a very good path.

BK - Although you consolidate a lot of the parameters I model individually, I come up with a similar number moving this from a biotech startup to an IBB pharma company (I do use the IBB PE though which is a bit lower than your PE). The only thing I would challenge is your last statement as I do not think big pharma would pay such a premium over the current stock price in a BO (limit is usually around 100%). Once we price in everything getting to a an $8B MC, the BO premium would drop further (40%-50%). Given WRs age and the frequency (or lack thereof) at which this opportunities present themselves, it is my guess that it is his goal to ride this out building out several iCTCs in the US/Europe and probably on in Australia and Asia eventually. Just don't think he is looking for a 3x (from his $9.15 purchase) at this point in his investing career. As long as the trial data continues to support expansion, think that is the route he will chose to go. I will be monitoring same.

Looks like this one is moving back up rapidly. More good news pending?

Nice Analysis.

Well.. we have been on here posting many times when the SP was getting crushed. Today is a different story and it feels pretty darn good. Short thesis of a poor launch leading to an early raise with the SP down has been hampered today. Looks like we are in for a rate cut here soon with about 92% odds now for a cut in Sept. https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html

We have a shift from big tech to more rate sensitive indices (IWM, XBI). You can see the bid constantly being reloaded and the 5 min retracements being bought.

If we hold 8.08 we have remounted the 20 EMA on daily. We are currently sitting at the 50 SMA on weekly of 8.50. Have a feeling that we will need some company positive news (Instead of just interest rate macro event) to break that 8.50. Hope I am wrong though. Who knows maybe short covering will do it.

Enjoying the day.

Appreiciate all your posts. Have had this on my watch list since the spring news and resultant pop.

I've not been active in the markets for over 20 years.... but about to dip my feet, but mostly in ETF, hi yield investments for retirement income, etc. So....

A morning of simple math: Let's assume $425 million for annual expenses - it's probably going up a bit with expansion, more trials, European rollout, more employees, etc.

Let's assume all in a treatment with Amtagvi and Proleukin produces revenue for Iovance of $425,000/patient on average (this covers for discounts, other expenses that may exist with ATCs, etc). I realize this is a conservative average but it makes the math easy. That means no more than 1,000 patients to break even. 2,350 patients for $1 billion in total revenue. With 70 ATCs by end of year, that's 1.2 patients/ATC/month for break even and 2.8 patients/ATC/month for $1 billion in revenue. Now, reduce your expenses, increase your net revenue and you have an even bigger winner. The company keeps talking about 3, 4, and 5 patients per ATC per month. Do your own math - it's still a big winner.

I did say simple math so please be gentle with your critiques.

Let's continue: Even with 2,000 patients annually and nothing more using my overly conservative numbers, you have net profit of $425 million or about $1.50 per share. Similar biotechs trade around 22x earnings, so with nothing more than this base operation IOVA is $33/share. Now let's throw in growth potential, more indications, new markets, frontline treatments, etc., we start seeing why some have $100/share and higher aspirations. They're not wrong for thinking it or believing it could be so in the coming years. If big pharma is going to acquire Iovance, they better bring a healthy check book sooner than later. IMHO of course.

Good luck to the longs.

Dude stfu

Short interest was up another 2 million shares. As of 06/28/2024, short interest was 56.4 million shares from the 54.6 million on the last report. I thought it would be mostly flat to slightly higher, but the shorts were persistent throughout June. Let the fear of being short begin. Higher highs this year and soon we'll have some of the reasons revealed. Good luck to the longs.

I just did too. Ahhhhhhhhh :)

NEWS, IOVA gets approval of Melanoma and Cancer research

Do you even read what you post? Your last post was very negative and now this one is very positive.
Can you please post links to your bipolar claims. Thanks

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174730616

I just used the "Ignore"... much better than Yahoo... individual is completely gone. It's like he is screaming into a vacuum.

It is just a FUD. We all here know that.

Everton44, go away now
Nobody believes a word you say.
Your lies n deception are welcome on Yahoo Finance, the original hub of lies n deception.
This board is for truthful posts & posters with integrity.
You have neither.
Bye Bye

#CureCancer

My last message came close to mixing some metaphors, so to that end:

"We'll burn that bridge when we come to it."
"Don't count your chickens before they hatch in one basket."
"It's not rocket surgery."

And my personal favorite, though not really a mixed metaphor:

"You can lead a horse to water, but you can't lead a horticulture."

And I didn't use all caps to make my point.

Have a great day!

IOVA TO BE BOUGHT OUT BY MERCK, NEWS TO COME

Good morning and good news out of the Stifel Cell Therapy Forum yesterday. The benefit of ears in many places allows us as a board of investors and traders to gain insights that we might otherwise miss trying to fly solo. But with public boards comes the risk of misinformation as well. Fortunately, most of us here have been around long enough to know when to question, when to accept, and when to ignore. To the many responsible posters that have shared on this board, I thank you for sharing and improving all of our chances at successful trading and investing.

Good luck to the longs.

Badgerkid

IOVA FDA DISAPPROVED IOVA DRUG DUE TO PATIENT DEATH!!!!!!

Great info. Thanks.

The following posts regarding IOVA appeared on another site today by the poster JGalt24. Iovance did speak at a private management fireside chat at Stifel's 2024 Virtual Cell Therapy Forum today, July 9th. Here's the posts:

(2:52 pm) "The timing of the move up today coincided with the move in Xbi, but Iova also presented at the Stifel Cell Therapy Conference at 11:30am and made an interesting comment a few minutes in when asked about timing of guidance moving forward. Bellemin-CFO, and Gastman-EVP Medical Affairs presented btw. Bellemin said they guided to how many pts were enrolled during Q1 call. During Q2 call, looking towards Q3, they will “go one step further”. I assume that means they will guide to:
a. #of pts actually treated or expected to be treated vs enrolled, or
b. actual revenues
I would guess (a) for this Q but would love to be surprised, he sounded very positive about it. Either way, this should help in removing some of the concern around lack of visibility and/or help analysts start to feel more confident in modeling future revenues."

(3:15 pm answering a question): "Not a Stifel client. Factset pulls in news from most of the sell side firms. I have access to several firms’ research, but Stifel isn’t one of them. Luckily was still able to get access through factset. Sometimes that works, sometimes not if it isn’t publicly available through companies’ website."

(3:32 pm): "A couple of other notes:
-On reimbursement: “not an issue”; no coverage for an individual pt has yet been denied; 200M lives covered in the US and growing as per plan
-Patient attrition in line with early CAR-T #’s and expected to improve at a similar pace; ATC’s getting better at selecting pts
-confirmed about 50 atc’s and 70 by y-e; ALL have enrolled pts at this point; some of the newer ones have surpassed those that were involved in trials
-Capacity: haven’t hit constraints yet at atc’s, some are talking about expanding or building around demand for this treatment
-commented that some physicians are creating their careers around cell therapy, reflecting excitement in the industry

All sounds very positive, just need to be patient for another couple of quarters to see consistent revenues"

I don't know this poster, but all stacks up to what we've heard before. Several very good takeaways. Enjoy.

Badgerkid

We will have some time before Iovance share price recovers but my humble advise (and remind me of this post) is be patient and hold your position. Why? the downside is 4$, the upside is 20$ to 30$ with conservatively 50% chances of both occurring.

Also there is a high probability that the two scenarios occur, a drop of 4$ followed by a rise of 20 to 30$. Brace for this possibility and be ready financially and psychologically and you will be rewarded.

I have by now 25% of my net assets in Iovance (I stopped mentioning nb of shares after being accused of braging on yahoo and I am not going anywhere and ready to increase further and wait 2 to 3 years to get my return.

Can it all go horribly wrong? Sure but I prefer to lose my investment then to be again cursing myself for selling now after it reaches 40$ (as I did last year for having sold Nvidia 2 years ago...).

Why in the world would IOVA do a 25 for 1 reverse split? They have enough cash on hand to last through the end of 2025. Someone is getting awfully desperate. Good news must be close. Just checked out yahoo finance. The shorts are out in full force.

Link?

REVERSE SPLIT CITY, LOVE IT!!!!!!!!!!!!!!!!

AWESOME SHORT HERE AS THE 25 TO 1N RS HELPS A LOT!!!!!

25 to 1 RS ouch